Zimmer sees FY13 adjusted EPS $5.65-$5.85, consensus $5.74 Sees FY13 revenue up 2.5%-4.5% on constant currency basis, consensus $4.63B. The Company estimates that foreign currency translation will decrease revenues by approximately 0.5% for the full year 2013, resulting in reported revenue growth between 2% and 4%. In 2013, the Company expects to continue global restructuring and transformation initiatives designed to streamline business operations and support functions. Savings from these initiatives will enable the Company to absorb the medical device excise tax, continue to support investments in innovation and commercialization of new products and technologies, expand global sales channels and drive sustained growth in earnings and cash flow. The programs to be completed in 2013 are expected to generate annualized pre-tax savings of more than $80 million, including $30 million to $40 million to be realized in 2013.
News For ZMH From The Last 14 Days
Check below for free stories on ZMH the last two weeks.
On The Fly: Analyst Upgrade Summary Today's noteworthy upgrades include: Achillion (ACHN) upgraded to Buy from Hold at Deutsche Bank... CNOOC (CEO) upgraded to Neutral from Underperform at Credit Suisse... Dollar General (DG) upgraded to Buy from Neutral at Sterne Agee... Equity Residential (EQR) upgraded to Hold from Underperform at Jefferies... HMS Holdings (HMSY) upgraded to Overweight from Equal Weight at First Analysis... HP (HPQ) upgraded to Buy from Neutral at Monness Crespi... Halcon Resources (HK) upgraded to Buy from Hold at MLV & Co.... KapStone (KS) upgraded to Buy from Hold at Deutsche Bank... Sportsman's Warehouse (SPWH) upgraded at RW Baird... Westlake Chemical (WLK) upgraded to Neutral from Reduce at SunTrust... WisdomTree (WETF) upgraded to Neutral from Sell at Citigroup... Zimmer (ZMH) upgraded to Outperform from Market Perform at William Blair.
Zimmer upgraded to Outperform from Market Perform at William Blair William Blair upgraded Zimmer Holdings to Outperform citing the recent pullback in shares and its belief the proposed Biomet acquisition will close.